Windlas Biotech share news, announcements and annual reports
NSE: WINDLASBSE: 543329Pharmaceuticals & BiotechnologySmall Cap
Windlas Biotech Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2021 · Issue price ₹460
Last close ₹876.10down ₹47.30 (5.12%)BSE ₹877.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹923.40.
30 Oct: open ₹920.80, high ₹921.70, low ₹865.50
52-week range of traded prices to 30 Oct 2026
₹697.40Low, 16 Mar 2026₹1,181.90High, 7 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,808 Cr1,237th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.22
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 3.11
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.72%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,27757.3% delivered
Windlas Biotech share news and announcements
325 announcements, routine notices left out, newest first. Page 3 of 7.
Feb 2025
11 Feb · Results
3 Feb · Analysts
3 Feb · Board meeting
Jan 2025
3 Jan · General Updates
1 Jan · Analysts
Dec 2024
11 Dec · Legal
Exchange has sought clarification from Windlas Biotech Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Nov 2024
22 Nov · Analysts
15 Nov · Analysts
15 Nov · Analysts
14 Nov · Analysts
12 Nov · Board meeting
12 Nov · Results
5 Nov · Analysts
Oct 2024
17 Oct · Analysts
7 Oct · Analysts
5 Oct · Analysts
5 Oct · Analysts
Sep 2024
24 Sep · Meeting
24 Sep · Analysts
17 Sep · Analysts
13 Sep · Analysts
12 Sep · Analysts
10 Sep · Analysts
10 Sep · Analysts
9 Sep · Corrigendum
Aug 2024
29 Aug · Updates
29 Aug · Corporate action
13 Aug · Board meeting
13 Aug · Results
6 Aug · Analysts
2 Aug · Board meeting
Jul 2024
9 Jul · Analysts
9 Jul · Analysts
1 Jul · Meeting
Jun 2024
25 Jun · Analysts
May 2024
29 May · Analysts
29 May · Analysts
20 May · Management